Beclabuvir is primarily used in the treatment of chronic hepatitis C virus (HCV) infection. It functions as a non-nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. By inhibiting this enzyme, beclabuvir effectively reduces the viral load in patients, aiding in the management and potential cure of the infection. It is often used in combination with other antiviral agents, such as daclatasvir and asunaprevir, to enhance efficacy and reduce the risk of resistance. This combination therapy is particularly beneficial for patients with specific HCV genotypes, offering a targeted approach to treatment. The use of beclabuvir has shown promising results in improving liver function and overall patient outcomes in clinical trials.